赛诺菲创新药可倍力获批上市

Group 1 - Sanofi's innovative drug, Kybella, received approval from the National Medical Products Administration for use in treating adults and adolescents aged 12 and above with acquired thrombotic thrombocytopenic purpura [2] - The approval process for Kybella in China was expedited, taking only 6 months from application submission to approval, thanks to government support for urgently needed rare disease treatments [1] Group 2 - The drug was showcased at the China International Import Expo, highlighting its significance in the market [1]